

**PATENT**

Docket No.: 4488-4000

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Bryan M. O'Hara

Serial No. : 10/010,129 Group Art Unit: 1614

Filed : December 6, 2001 Examiner: TBA

For : NOVEL COMPOUNDS THAT ENHANCE DIMERIZATION OF THE  
SUBUNITS OF HIV-1 REVERSE TRANSCRIPTASE HAVING  
MUTATIONS ASSOCIATED WITH RESISTANCE TO  
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORSAssistant Commissioner of Patents  
Washington, D.C. 20231**REVOCATION OF POWER OF ATTORNEY UNDER 37 C.F.R. §1.36 AND**  
**APPOINTMENT OF ATTORNEY**

Sir:

PROGENICS PHARMACEUTICALS, INC. is the assignee of the entire right, title and interest in the above-identified patent application, by an Assignment executed on, and recorded December 6, 2001, in the United States Patent and Trademark Office at Reel 012383, Frame 0826.

As assignee of record of the entire interest of the above-identified application, I hereby revoke all powers of attorney previously given.

I hereby appoint the following attorneys and/or agents with full power of substitution and revocation, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith:

David H. Pfeffer (Reg. No. 19,825), Harry C. Marcus (Reg. No. 22,390), Robert E. Paulson (Reg. No. 21,046), Stephen R. Smith (Reg. No. 22,615), Kurt E. Richter (Reg. No. 24,052), J.

Docket No.: 4488-4000

Robert Dailey (Reg. No. 27,434), Eugene Moroz (Reg. No. 25,237), John F. Sweeney (Reg. No. 27,471), Arnold I. Rady (Reg. No. 26,604), Christopher A. Hughes (Reg. No. 26,914), William S. Feiler (Reg. No. 26,728), Joseph A. Calvaruso (Reg. No. 28,287), James W. Gould (Reg. No. 28,859), Richard C. Komson (Reg. No. 27,913), Israel Blum (Reg. No. 26,710), Bartholomew Verdirame (Reg. No. 28,483), Maria C.H. Lin (Reg. No. 29,323), Joseph A. DeGirolamo (Reg. No. 28,595), Michael P. Dougherty (Reg. No. 32,730), Seth J. Atlas (Reg. No. 32,454), Andrew M. Riddles (Reg. No. 31,657), Bruce D. DeRenzi (Reg. No. 33,676), Mark J. Abate (Reg. No. 32,527), John T. Gallagher (Reg. No. 35,516), Steven F. Meyer (Reg. No. 35,613), Kenneth H. Sonnenfeld (Reg. No. 33,285), Tony V. Pezzano (Reg. No. 38,271), Andrea L. Wayda (Reg. 43,979), Walter G. Hanchuk (Reg. No. 35,179), John W. Osborne (Reg. No. 36,231), Robert K. Goethals (Reg. No. 36,813), Peter N. Fill (Reg. No. 38,876), Mary J. Morry (Reg. No. 34,398), Kenneth S. Weitzman (Reg. No. 36,306), Richard Straussman (Reg. No. 39,847), Stephen J. Manetta (Reg. No. 40,426), and Caryn DeHoratius (Reg. No. 45,881) of Morgan & Finnegan, L.L.P. whose address is: 345 Park Avenue, New York, New York, 10154; and Michael S. Marcus (Reg. No. 31,727), and John E. Hoel (Reg. No. 26,279), of Morgan & Finnegan, L.L.P., whose address is 1775 Eye Street, Suite 400, Washington, D.C. 20006.

The correspondence address to which all communications about this application are to be directed is as follows:

Eugene Moroz  
MORGAN & FINNEGIAN, L.L.P.  
345 Park Avenue  
New York, NY 10154  
(212) 415-8513 (Phone)  
(212) 751-6849 (Facsimile)

Respectfully submitted,

On behalf of PROGENICS PHARMACEUTICALS, INC.

Date: January 15, 2003

By: Paul J. Madden

(Signature of person authorized to sign on behalf of Assignee)

Paul J. Madden  
(Typed or printed name of person authorized to sign on behalf of Assignee)

Chairman,  
Chief Executive Officer, and  
Chief Scientific Officer  
(Title of person authorized to sign on behalf of Assignee)